Dr. O'Connor on the Role of Obinutuzumab in Follicular Lymphoma

Owen O'Connor, MD, PhD
Published: Monday, Nov 27, 2017



Owen O'Connor, MD, PhD, professor of medicine and Experimental Therapeutics, director of the Center for Lymphoid Malignancies, Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, discusses the role of obinutuzumab (Gazyva) in the treatment of patients with follicular lymphoma.

Obinutuzumab is reported to have better antibody dependent cell-mediated cytotoxicity (ADCC) in comparison to rituximab (Rituxan), explains O'Connor. The GADOLIN study investigated patients with refractory follicular lymphoma, which is a population that does not have many treatment options available

The GADOLIN study compared obinutuzumab plus bendamustine followed by obinutuzumab maintenance versus bendamustine alone.
 
SELECTED
LANGUAGE


Owen O'Connor, MD, PhD, professor of medicine and Experimental Therapeutics, director of the Center for Lymphoid Malignancies, Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, discusses the role of obinutuzumab (Gazyva) in the treatment of patients with follicular lymphoma.

Obinutuzumab is reported to have better antibody dependent cell-mediated cytotoxicity (ADCC) in comparison to rituximab (Rituxan), explains O'Connor. The GADOLIN study investigated patients with refractory follicular lymphoma, which is a population that does not have many treatment options available

The GADOLIN study compared obinutuzumab plus bendamustine followed by obinutuzumab maintenance versus bendamustine alone.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x